Launched in 2020, Lenstar Myopia is the market-leading, comprehensive solution based on the established Lenstar 900 optical biometer combined with powerful EyeSuite Myopia software.

Lenstar Myopia provides state-of-the-art myopia management. It enables the eye care professional to:

• Obtain fast, precise measurements and quickly and confidently interpret data to detect myopia
• Utilize this wealth of data to make an accurate diagnosis to confidently predict myopia’s onset and progression
• Clearly communicate easy-to-understand information to facilitate true patient/parent education, allowing them to actively participate in the myopia management process
• Decide on a form of treatment, monitor its progress, adjust where necessary, and control myopia progression.

Early myopia detection allows for conservative therapies, which may be more effective when started sooner. Implementing a comprehensive screening program for children can help in this regard. The Lenstar Myopia is a particularly powerful tool for myopia detection due to its high-precision biometric data and fast measurement process. Eye care professionals can use this technology to identify onsetting myopia cases that would otherwise go undetected.

The Lenstar Myopia was the first myopia management solution in the market to truly facilitate patient and parent education. EyeSuite Myopia combines all collected data in a highly flexible and customizable report based on myopia.care™. The report provides parents with easy-to-understand information in familiar traffic light colors, enabling them to actively participate in the myopia management process, and commit to and support the appropriate treatment for their child.

It is well-documented that the global myopia pandemic continues to progress rapidly. Most eye care professionals are familiar with the "Report of the Joint World Health Organization—Brien Holden Vision Institute Global Scientific Meeting" and the prediction that myopia will affect around 50% of the world’s population by 2050. Furthermore, one in ten myopic people will likely develop high myopia, which, if left untreated, can have drastic consequences in adulthood. With the increase in myopia cases worldwide, myopia detection, education, and management are in high demand. Lenstar Myopia is the market-leading, comprehensive solution for myopia management.

HS-UK has a strategic partnership with HOYA Lens UK to provide the LENSTAR Myopia by HOYA.

LENSTAR Myopia by HOYA provides diagnostics and treatment for myopia, with information and education for patients and their parents about myopia and its progression. Combining the LENSTAR Myopia with HOYA Lens UK’s easy to prescribe MiYOSMART spectacle lens, provides a comprehensive myopia management solution for children.

Launched in 2020, the MiYOSMART lens provides a full vision correction and has a ring-shaped treatment zone to slow down myopia progression. The combination of the focus zone and treatment zone provides clear vision and manages myopia simultaneously.

MiYOSMART lenses use revolutionary Defocus Incorporated Multiple Segments (D.I.M.S.) Technology clinically proven to slow down myopia progression on average by 60% in children ages 8-13*.

For further information on the Lenstar Myopia by HOYA and MiYOSMART lenses please email supportingyou@hoya.co.uk or, alternatively, visit https://hsuk.co/LenstarMyopiaHOYA.

_{*Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739.}

At Haag-Streit UK, we are always happy to support our customers with any queries on our range of products. As a first port of call, we have put together a comprehensive list of myopia management frequently asked questions.